| Indiana University Research & Technology Corporation Patent applications |
| Patent application number | Title | Published |
|---|
| 20120016036 | MATERIAL AND METHODS FOR TREATING DEVELOPMENTAL DISORDERS INCLUDING COMORBID AND IDIOPATHIC AUTISM - Subjects who were diagnosed with either comorbid or idiopathic autism were treated with acamprosate. Patients generally showed marked improvements in primary outcomes as assessed using, for example, standard clinic measures for functionality including the Clinical Global Impressions Improvement (CGI-I) and the Clinical Global Impressions Severity (CGI-S) scales. | 01-19-2012 |
| 20110301108 | MATERIALS AND METHODS FOR SENSITIZING MULTIDRUG RESISTANT CELLS - Disclosed herein are materials and methods for sensitizing multidrug resistant cancer cells that express ABCG2 and related proteins members of a family of ATP-binding transporter superfamily that mediate drug efflux found in some types of multidrug resistant caner cells. A series of compounds, including (N-(4-chlorophenyl)-2-[(6-{[4,6-di(4-morpholinyl)-1,3,5-tri-azin-2-yl]amino}-1,3-benzothiazol-2-yl)sulfanyl]acetamide), specifically inhibits ABCG2 and can be used to boost the bio-avail-ability of one or more effective cancer killing drugs, making it possible to use certain widely used chemotherapeutic reagent to treat multidrug resistance cancers. Using these compounds in combination with chemotherapeutic drugs that are substrates for ABCG2 and related proteins may also find utility in treating cancer cells that are not currently identified as multi-drug resistant Additionally, these compounds appear to accelerate the intercellular degradation of ABCG2 and related proteins. They are not toxic to animals at levels at which they effect the activity of ABCG2 expressed in multi-drug resistant cancer lines. | 12-08-2011 |
| 20110288652 | MATERIALS AND METHODS FOR TREATING CRITICALLY SIZED DEFECTS IN MOUSE BONE - Scaffolds equipped to include biologically active reagents such as proteins sized and engineered specifically for use in a mouse were made and implanted into mice. The scaffold was specifically designed for use in a mouse femoral critical sized defect Scaffolds. Special care was taken when casting these scaffolds to ensure that the material used to form the body of the scaffold did not include defects such as a large number of macroscopic holes that could compromise the structural integrity of these very small devices. Some of these scaffolds include a hollow center that accommodate a rod that ran the longitudinal length of the scaffold extending into the adjacent bone to anchor the scaffold to the bone. Scaffold also include at least one channel that extended from the outside of the structure towards its center and could be hold a liquid or paste comprising for example exogenous BMP-2. | 11-24-2011 |
| 20110269636 | MATERIALS AND METHODS FOR IDENTIFYING PATIENTS AT HEIGHTEN RISK FOR DEVELOPING HER2+ RELATED BRAIN TUMORS - Aspects of the invention include methods for identifying patients with HER2+ cancers that are at a heightened risk for developing brain metastasis within three years of having been diagnosed with HER2+ cancer. Some embodiments are methods that include the steps of contacting at least a portion of the tumor tissue from patients with probes that interact with the products of a set of thirteen genes that are expressed in these patients at markedly higher levels than in similarly situated patients that are not a heightened risk for developing brain metastasis within this three year window. In some embodiments the tissue samples are assayed from the presence of RNA indicative of the expression of member of a set of 13 genes identified as being differentially expressed in patients with and without a heightened risk for developing brain metastasis. | 11-03-2011 |
| 20080250565 | Relocatable Stereotactic Immobilization Apparatus - A patient immobilization frame is provided that can be secured to a patient table in a radiation therapy facility. The frame includes fiducials integrated into the bottom panel of the frame. The frame is provided with a removable locking mechanism for locking the frame to the patient table. Each side walls of the frame defines a forward cut-out and a mid-side cut-out to accommodate larger girth patients. A panel insert is provided to close the mid-side cut-outs when the additional space is not required for the patient. The frame further includes an abdomen compression device supported by a cross bar that is movably mountable to the frame. The device includes a compression plate configured to contact the patient and a compression mechanism between the cross bar and the compression plate. A pressure transducer may be incorporated between the compression plate and the cross bar. | 10-16-2008 |
